This website uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Further information



Main objectives

NANEMIAR aims to develop a first-of-its-kind nanomedicine for β-thalassemia.

Specific objectives

NANEMIAR is divided into 3 specific objectives:

      1. Work package 1 (WP1) is focused on establishing the activity and safety of the proposed therapeutic in cell models and animal models.
      2. Work package 2 (WP2) is aimed at establishing a proof-of-concept for efficacy of the therapeutic in a thalassemic mouse model.
      3. Work package 3 (WP3) will be dedicated to delivering the first safety and efficacydata on hematopoietic stem cells from β-thalassemia patients.
More information about NANEMIAR available on CORDIS – EU research results


mRNA, erythropoiesis, lipid nanoparticles, targeting, health, congenital anemia

NANEMIAR ambition


Work plan